XML 35 R18.htm IDEA: XBRL DOCUMENT
v3.20.4

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2020
Stock-Based Compensation [Abstract] |
Stock-Based Compensation |
9. | Stock–Based Compensation
At December 31, 2020, the Company had the following stock-based employee compensation plans: Equity Incentive Plans In April 2010, the Company’s board of directors approved the Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan (the “2010 Omnibus Incentive Plan”). This plan was approved by the Company’s stockholders at the Company’s 2010 Annual Meeting of Stockholders held in May 2010. The 2010 Omnibus Incentive Plan provides for granting of a variety of equity-based awards including stock options, stock appreciation rights, restricted stock, restricted stock units, other share-based awards, performance cash, performance shares and performance units to executives, other employees, independent consultants and directors of the Company and its subsidiaries. Options granted under the 2010 Omnibus Incentive Plan are generally non-qualified stock options, but the 2010 Omnibus Incentive Plan permits some stock options granted to qualify as “incentive stock options” under the U.S. Internal Revenue Code. The exercise price of a stock option generally is equal to the fair market value of the Company’s common stock on the stock option grant date. The contractual term of a stock option granted under the 2010 Omnibus Incentive Plan is seven years. Currently, all shares issued upon the exercise of stock options are from the Company’s treasury shares. Subject to certain adjustments, 7.0 million shares were authorized for issuance under the 2010 Omnibus Incentive Plan. On June 3, 2013, the Company’s stockholders approved an Amended and Restated 2010 Omnibus Incentive Plan, which among other things increased the number of shares available for awards by 3.2 million shares. On May 24, 2016, the Company’s stockholders approved a Second Amended and Restated 2010 Omnibus Incentive Plan, which among other things increased the number of shares available for awards by 3.8 million shares. On June 3, 2020, the Company’s stockholders approved a Third amended and Restated 2010 Omnibus Incentive Plan, which among other things increased the number of shares available for awards by 5.9 million shares. The fair value of stock option awards was estimated using the Black-Scholes option-pricing model with the following assumptions and weighted-average fair values as follows:
|  | December 31, |
Stock Options: |  | 2020 |  |  | 2019 |  |  | 2018 |
Weighted-average grant date fair value of grants |  | $ | 8.59 |  |  | $ | 19.72 |  |  | $ | 24.72 |
Risk-free interest rate (1) |  |  | 1.4 | % |  |  | 2.5 | % |  |  | 2.6 | %
Dividend yield (2) |  |  | 2.9 | % |  |  | 2.7 | % |  |  | 2.6 | %
Expected volatility (3) |  |  | 40.7 | % |  |  | 42.4 | % |  |  | 45.6 | %
Expected life in months (4) |  | 59 months |  |  | 60 months |  |  | 66 months |
(1) | The risk-free interest rate is based upon the rate on a zero-coupon U.S. Treasury bill, for periods within the contractual life of the option, in effect at the time of the grant.
(2) | The dividend yield is based on the average of historical stock prices and actual dividends paid.
(3) | Expected volatility is based on the historical volatility of the Company’s stock price, over a period similar to the expected life of the option.
(4) | The expected term of the option is based on the historical employee exercise behavior, the vesting terms of the respective option, and a contractual life of either seven or ten years.
Options under the plans as of December 31, 2020 and changes during the year ended December 31, 2020 were as follows:
|  | Shares (in thousands) |  |  | Weighted- average Exercise Price |  |  | Weighted- average Remaining Contractual Term (in years) |  |  | Aggregate Intrinsic Value (in thousands) |
Options activity – service based |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2019 |  |  | 962.5 |  |  | $ | 41.11 |  |  |  |  |  |  |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |
Exercised |  |  | (114.7 | ) |  |  | 32.82 |  |  |  |  |  |  |
Forfeited/cancelled/expired |  |  | (77.2 | ) |  |  | 77.39 |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 770.6 |  |  |  | 38.71 |  |  |  | 2.06 |  |  | $ | 13,410 |
Exercisable at December 31, 2020 |  |  | 770.6 |  |  |  | 38.71 |  |  |  | 2.06 |  |  |  | 13,410 |
Options activity – performance based |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2019 |  |  | 2,158.4 |  |  | $ | 61.75 |  |  |  |  |  |  |  |  |
Granted |  |  | 1,079.3 |  |  |  | 30.45 |  |  |  |  |  |  |  |  |
Exercised |  |  | (116.2 | ) |  |  | 31.13 |  |  |  |  |  |  |  |  |
Forfeited/cancelled/expired |  |  | (723.5 | ) |  |  | 69.82 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 2,398.0 |  |  |  | 46.71 |  |  |  | 4.89 |  |  | $ | 31,720 |
Exercisable at December 31, 2020 |  |  | 565.6 |  |  |  | 49.26 |  |  |  | 3.05 |  |  |  | 5,713 |
Options activity – all options |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2019 |  |  | 3,120.9 |  |  | $ | 55.38 |  |  |  |  |  |  |  |  |
Granted |  |  | 1,079.3 |  |  |  | 30.45 |  |  |  |  |  |  |  |  |
Exercised |  |  | (230.9 | ) |  |  | 31.97 |  |  |  |  |  |  |  |  |
Forfeited/cancelled/expired |  |  | (800.7 | ) |  |  | 70.55 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 3,168.6 |  |  |  | 44.76 |  |  |  | 4.20 |  |  | $ | 45,130 |
Exercisable at December 31, 2020 |  |  | 1,336.3 |  |  |  | 43.18 |  |  |  | 2.48 |  |  |  | 19,124 |
The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between the Company’s closing stock price on the last trading day of the respective years and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2020. This amount varies based on the fair market value of the Company’s stock. Cash proceeds, tax benefits and intrinsic value related to total stock options exercised during 2020, 2019 and 2018, were as follows (U.S. dollars in thousands):
|  | December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
Cash proceeds from stock options exercised |  | $ | 7,419 |  |  | $ | 368 |  |  | $ | 13,908 |
Tax (expense) / benefit realized for stock options exercised |  |  | (459 | ) |  |  | 430 |  |  |  | 3,217 |
Intrinsic value of stock options exercised |  |  | 5,232 |  |  |  | 934 |  |  |  | 11,855 |
Nonvested restricted stock awards as of December 31, 2020 and changes during the year ended December 31, 2020 were as follows:
|  | Number of Shares (in thousands) |  |  | Weighted-average Grant Date Fair Value |
Nonvested at December 31, 2019 |  |  | 573.1 |  |  | $ | 58.99 |
Granted |  |  | 614.6 |  |  |  | 38.58 |
Vested |  |  | (220.1 | ) |  |  | 56.50 |
Forfeited |  |  | (36.5 | ) |  |  | 51.98 |
Nonvested at December 31, 2020 |  |  | 931.1 |  |  | $ | 46.38 |
Stock-based compensation expense is recognized on a straight-line basis, except for performance-based awards for which expense is recognized using a graded-attribution method if the results are materially different than the straight-line method. The Company recognized $0.3 million, $2.6 million and $3.1 million of expense related to service condition stock options in 2020, 2019 and 2018, respectively; and $13.9 million, $11.5 million and $11.2 million of expense related to service condition restricted stock units in 2020, 2019 and 2018, respectively. For performance stock options and performance stock units, an expense is recorded each period for the estimated expense associated with the projected achievement of the performance-based targets. The Company recognized $9.9 million of expense, $4.1 million of income and $12.2 million of expense related to performance stock options in 2020, 2019 and 2018, respectively; and none, $0.1 million of expense and $0.1 million of income related to performance stock units in 2020, 2019 and 2018, respectively. The amount in 2019 reflects the reversal of stock compensation for awards no longer expected to vest. As of December 31, 2020, there was $8.6 million of unrecognized stock-based compensation expense related to nonvested stock option awards. That cost is expected to be recognized over a weighted-average period of 1.5 years. As of December 31, 2020, there was $28.0 million of unrecognized stock-based compensation expense related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 2.6 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration